Triple Negative Breast Cancer (TNBC): Non-genetic Tumor Heterogeneity and Immune Microenvironment: Emerging Treatment Options

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2022 Jul 25

PMID 35872332

Authors

Jae Young So

Joyce Ohm

Stan Lipkowitz

Li Yang

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor heterogeneity and lack of biomarkers are thought to be some of the most difficult challenges driving therapeutic resistance and relapse. This review will summarize current therapy for TNBC, studies in treatment resistance and relapse, including data from recent single cell sequencing. We will discuss changes in both the transcriptome and epigenome of TNBC, and we will review mechanisms regulating the immune microenvironment. Lastly, we will provide new perspective in patient stratification, and treatment options targeting transcriptome dysregulation and the immune microenvironment of TNBC patients.

Citing Articles

Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing.

Wu S, Jiang B, Li Z, Tang Y, Luo L, Feng W Breast Cancer Res. 2025; 27(1):31.

PMID: 40045365 PMC: 11881325. DOI: 10.1186/s13058-025-01980-4.

Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.

Alalhareth I, Alyami S, Alshareef A, Ajeibi A, Al Munjem M, Elfifi A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006021 PMC: 11858621. DOI: 10.3390/ph18020207.

Discovery of a new mitophagy-related gene signature for predicting the outlook and immunotherapy in triple-negative breast cancer.

Liu G, Yu G, Yin D, Ma J Sci Rep. 2025; 15(1):6794.

PMID: 40000809 PMC: 11861672. DOI: 10.1038/s41598-025-91613-9.

The mechanism underlying metastasis in triple-negative breast cancer: focusing on the interplay between ferroptosis, epithelial-mesenchymal transition, and non-coding RNAs.

Chen Z, Zhao Y Front Pharmacol. 2025; 15:1437022.

PMID: 39881868 PMC: 11774878. DOI: 10.3389/fphar.2024.1437022.

Pristimerin Promotes Ubiquitination of HSPA8 and Activates the VAV1/ERK Pathway to Suppress TNBC Proliferation.

Liu Q, Fan Q, Chen J, Liu J, Li Y, Luo Q Adv Sci (Weinh). 2025; 12(10):e2413174.

PMID: 39813169 PMC: 11904939. DOI: 10.1002/advs.202413174.

References

Feinberg A, Tycko B . The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-53. DOI: 10.1038/nrc1279. View

Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A . Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021; 39(10):1388-1403.e10. DOI: 10.1016/j.ccell.2021.08.008. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F . High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet. 2019; 51(6):1060-1066. DOI: 10.1038/s41588-019-0424-9. View

Coussy F, El-Botty R, Chateau-Joubert S, Dahmani A, Montaudon E, Leboucher S . BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci Transl Med. 2020; 12(531). PMC: 8662740. DOI: 10.1126/scitranslmed.aax2625. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Sharma D, Saxena N, Davidson N, Vertino P . Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006; 66(12):6370-8. PMC: 2925469. DOI: 10.1158/0008-5472.CAN-06-0402. View

Pang Y, Gara S, Achyut B, Li Z, Yan H, Day C . TGF-β signaling in myeloid cells is required for tumor metastasis. Cancer Discov. 2013; 3(8):936-51. PMC: 4678771. DOI: 10.1158/2159-8290.CD-12-0527. View

10.

Deblois G, Madani Tonekaboni S, Grillo G, Martinez C, Kao Y, Tai F . Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. Cancer Discov. 2020; 10(9):1312-1329. DOI: 10.1158/2159-8290.CD-19-1493. View

11.

Mathe A, Wong-Brown M, Locke W, Stirzaker C, Braye S, Forbes J . DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients. Sci Rep. 2016; 6:33435. PMC: 5037364. DOI: 10.1038/srep33435. View

12.

Seoane J, Kirkland J, Caswell-Jin J, Crabtree G, Curtis C . Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nat Med. 2019; 25(11):1721-1727. PMC: 7220800. DOI: 10.1038/s41591-019-0638-5. View

13.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

14.

Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B . Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev. 2015; 29(24):2547-62. PMC: 4699384. DOI: 10.1101/gad.269522.115. View

15.

Flavell R, Sanjabi S, Wrzesinski S, Licona-Limon P . The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010; 10(8):554-67. PMC: 3885992. DOI: 10.1038/nri2808. View

16.

Lyons Y, Wu S, Overwijk W, Baggerly K, Sood A . Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2018; 1(1):26. PMC: 5871917. DOI: 10.1038/s41698-017-0031-0. View

17.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

18.

Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S . Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2019; 17(2):91-107. DOI: 10.1038/s41571-019-0267-4. View

19.

Pineda B, Diaz-Lagares A, Perez-Fidalgo J, Burgues O, Gonzalez-Barrallo I, Crujeiras A . A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Clin Epigenetics. 2019; 11(1):33. PMC: 6381754. DOI: 10.1186/s13148-019-0626-0. View

20.

Huo X, Li J, Zhao F, Ren D, Ahmad R, Yuan X . The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021; 21(1):78. PMC: 7816481. DOI: 10.1186/s12885-021-07791-y. View